ReviewClinical pharmacokinetics2008
Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.
Review in Clinical pharmacokinetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Antimicrobial agents and chemotherapy · 2014Trial
- Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.Rapid communications in mass spectrometry : RCM · 2018Article
- Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.European journal of drug metabolism and pharmacokinetics · 2017Review
- Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.International journal of clinical pharmacy · 2017Article
- Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.Clinical drug investigation · 2015Article
- Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.Therapeutic advances in infectious disease · 2014Article
- Zidovudine and Lamivudine for HIV Infection.Clinical medicine reviews in therapeutics · 2010Article
- Long-term treatment of patients with HIV-1: the role of atazanavir.HIV/AIDS (Auckland, N.Z.) · 2010Article
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.European journal of clinical pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatic and renal insufficiency due to co-infection, alcoholism, diabetes mellitus, family history, adverse effects of antiretrovirals and other factors are commonly seen in HIV-infected patients. Therefore, the use of antiretrovirals in this patient setting requires attention to the pharmacokinetic issues that clinicians must consider when prescribing highly active antiretroviral therapy for these patients. This review summarizes the current knowledge of the use of antiretrovirals in patients with hepatic or renal impairment, and makes dosing recommendations for this subpopulation of HIV-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.